ArticleOncotarget2017

ERpS294 is a biomarker of ligand or mutational ERα activation and a breast cancer target for CDK2 inhibition.

Gary K Scott et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.